Menu
[et_pb_section fb_built="1" _builder_version="4.24.1" _module_preset="default" width="100%" min_height="1334px" global_colors_info="{}" theme_builder_area="post_content"][et_pb_row _builder_version="4.24.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_column type="4_4" _builder_version="4.24.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][et_pb_text _builder_version="4.24.1" _module_preset="default" text_text_color="#0A2E4A" global_colors_info="{}" theme_builder_area="post_content"]
SOPHiA GENETICS™ thrilled to be back at this year’s Healthcare Information and Management Systems Society annual meeting. Join us from March 11th – 15th in Orlando, Fl, where more than 33K health professionals from around the globe will gather to discuss how we can harness the power of information and technology to shape the future of health.
Stop by booth #4727 to meet our team and to learn how our cloud-based SOPHiA DDMTM Platform is empowering clinical researchers to break data siloes and improve knowledge sharing. You can also chat with our experts and get a sneak peak to SOPHiA DDM™ Platform GEN 2.
LUNCH & LEARN
Unleashing Healthcare Potential: Advancing Decision-Making through AI-Powered Multimodal Analysis
Thursday, March 14
11:15 am -12:15 pm
Room: W203 C
Capturing the complexity of human health and disease through machine learning analysis of multiple and diversified data sets has the potential to improve the precision and efficiency of clinical decision making, by providing more accurate and informative insights than the sum of their parts.
Join us at this lunch and learn session to discover how the secure and compliant SOPHiA DDM™ Platform assembles, standardizes, and transforms multimodal data into accessible data-driven insights.
The SOPHiA DDM™️ Platform simplifies data management through seamless and automated integration with data generation technologies, EHR, LIMS, and interpretation tools whilst maintaining institutional ownership of samples and data. Leveraging on Microsoft Azure Cloud infrastructure and capabilities, SOPHiA DDM™️ streamlines the integration of longitudinal oncology data from multiple sources and modalities – from omics to clinical and biological data. CPUs operate in tandem with powerful NVIDIA GPUs to efficiently process the resulting computationally heavy workloads, scaling to growing needs.
We will discuss and demo how the SOPHiA DDM™ Platform enables multimodal data visualization (longitudinal view of patient data across the care journey) and cohorting (contextualizing patients or patient groups with others in one of the largest networks of global institutions) to facilitate the identification of multimodal predictive signatures, as well as treatment response patterns and trends.
To finish, we warmly welcome you to participate in the interactive panel discussion, where you will have the opportunity to ask questions and converse with our experts.
[/et_pb_text][et_pb_button button_url="https://forms.office.com/pages/responsepage.aspx?id=ZtVnJUxgikCKYFXQ3J2daymmtq2SRk1JqHS_iNVHeoRURjFYQzI0SDU3MUYwRlBTM05GR0NRU0NVTS4u" url_new_window="on" button_text="Register Now" button_alignment="center" _builder_version="4.24.1" _module_preset="default" custom_button="on" button_text_color="#FFFFFF" button_bg_color="#E3295C" button_border_color="#FFFFFF" global_colors_info="{}" theme_builder_area="post_content"][/et_pb_button][et_pb_image src="https://www.sophiagenetics.com/wp-content/uploads/2024/02/HIMSS-Summit2024_SM-16-9.png" alt="SOPHiA GENETICS at HIMSS 2024" title_text="HIMSS Summit2024_SM 16-9" _builder_version="4.24.1" _module_preset="default" global_colors_info="{}" theme_builder_area="post_content"][/et_pb_image][et_pb_text _builder_version="4.24.1" _module_preset="default" text_text_color="#0A2E4A" global_colors_info="{}" theme_builder_area="post_content"]
Presented by
Abhimanyu (Abhi) Verma, MBA, SVP and Chief Technology Officer, SOPHiA GENETICS
David Rhew, M.D., Global Chief Medical Officer & VP of Healthcare, Microsoft
Jeff Gaudet, Ph.D., Medical Affairs Manager, SOPHiA GENETICS
[/et_pb_text][et_pb_text _builder_version="4.24.2" _module_preset="default" theme_builder_area="post_content" hover_enabled="0" sticky_enabled="0" custom_padding="0px|||179px|false|false"]
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
